Skip to content
Open access · CC-BY via OpenAlex

Rapamycin inhibits B16 melanoma cell viability in vitro and in vivo by inducing autophagy and inhibiting the mTOR/p70‑S6k pathway

Penghui Wang, Haifang Zhang, Kaikai Guo, Chun Liu, Shimin Chen, Bao-Peng Pu, Sirun Chen, Tong Feng, Hanyi Jiao, Chang Gao

Oncology Letters · 2024 · ▲ 15 citations

Abstract

mTOR(definition)-inhibiting drug studied for extending healthspan and lifespan." style="text-decoration:underline dotted; text-underline-offset:2px; cursor:help;">Rapamycin(definition) is an immunosuppressant that has been shown to prevent tumor growth following organ transplantation. However, its exact mode of antitumor action remains unknown. The present study used the B16‑F10 (B16) murine melanoma model to explore the antitumor mechanism of rapamycin, and it was revealed that rapamycin reduced B16 cell viability in vitro and in vivo. In addition, in vitro and in vivo, the results of western blotting showed that rapamycin reduced Bcl2 expression, and enhanced the protein expression levels of cleaved caspase 3 and Bax, indicating that it can induce the apoptosis of B16 melanoma cells. Furthermore, the results of cell cycle analysis and western blotting showed that rapamycin induced B16 cell cycle arrest in the G1 phase, based on the reduction in the protein expression levels of CDK1, cyclin D1 and CDK4, as well as the increase in the percentage of cells in G1 phase. Rapamycin also significantly increased the number of autophagosomes in B16 melanoma cells, as determined by transmission electron microscopy. Furthermore, the results of RT‑qPCR and western blotting showed that rapamycin upregulated the protein expression levels of microtubule‑associated protein light chain 3 (LC3) and Beclin‑1, while downregulating the expression of p62 in vitro and in vivo, thus indicating that rapamycin could trigger cellular autophagy(definition). The present study revealed that rapamycin in combination with chloroquine (CQ) further increased LC3 expression compared with that in the CQ group, suggesting that rapamycin induced an increase in autophagy in B16 cells. Furthermore, the results of western blotting showed that rapamycin blocked the phosphorylation of p70 ribosomal S6 kinase (p70‑S6k) and mammalian target of rapamycin (mTOR) proteins in vitro and in vivo, thus suggesting that rapamycin may exert its antitumor effect by inhibiting the phosphorylation of the mTOR/p70‑S6k pathway. In conclusion, rapamycin may inhibit tumor growth by inducing cellular G1 phase arrest and apoptosis. In addition, rapamycin may exert its antitumor effects by inducing the autophagy of B16 melanoma cells in vitro and in vivo, and the mTOR/p70‑S6k signaling pathway may be involved in this process.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.3892/ol.2024.14273
Canonical
link ↗
Fetched
2026-11-07 MST

Cite this

APA
Wang, P., Zhang, H., Guo, K., Liu, C., Chen, S., Pu, B., Chen, S., Feng, T., Jiao, H., &amp; Gao, C. (2024). Rapamycin inhibits B16 melanoma cell viability in vitro and in vivo by inducing autophagy and inhibiting the mTOR/p70‑S6k pathway. <em>Oncology Letters</em>. https://doi.org/10.3892/ol.2024.14273
Vancouver
Wang P, Zhang H, Guo K, Liu C, Chen S, Pu B, et al. Rapamycin inhibits B16 melanoma cell viability in vitro and in vivo by inducing autophagy and inhibiting the mTOR/p70‑S6k pathway. Oncology Letters. 2024. doi:10.3892/ol.2024.14273.
BibTeX
@article{penghui2024Rapamy, title = {Rapamycin inhibits B16 melanoma cell viability in vitro and in vivo by inducing autophagy and inhibiting the mTOR/p70‑S6k pathway}, author = {Penghui Wang and Haifang Zhang and Kaikai Guo and Chun Liu and Shimin Chen and Bao-Peng Pu and Sirun Chen and Tong Feng and Hanyi Jiao and Chang Gao}, journal = {Oncology Letters}, year = {2024}, doi = {10.3892/ol.2024.14273}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings